Mutations in interferon regulatory factor 6 (IRF6) account for~70% of cases of Van der Woude syndrome (VWS), the most common syndromic form of cleft lip and palate. In 8 of 45 VWS-affected families lacking a mutation in IRF6, we found coding mutations in grainyhead-like 3 (GRHL3). According to a zebrafish-based assay, the disease-associated GRHL3 mutations abrogated periderm development and were consistent with a dominant-negative effect, in contrast to haploinsufficiency seen in most VWS cases caused by IRF6 mutations. In mouse, all embryos lacking Grhl3 exhibited abnormal oral periderm and 17% developed a cleft palate. Analysis of the oral phenotype of double heterozygote (Irf6 þ/À ;Grhl3 þ/À ) murine embryos failed to detect epistasis between the two genes, suggesting that they function in separate but convergent pathways during palatogenesis. Taken together, our data demonstrated that mutations in two genes, IRF6 and GRHL3, can lead to nearly identical phenotypes of orofacial cleft. They supported the hypotheses that both genes are essential for the presence of a functional oral periderm and that failure of this process contributes to VWS. These authors contributed equally to this work *Correspondence: myriam.peyrard@ki.se (M.P.-J.), juha.kere@ki.se (J.K.) http://dx.
Introduction
Grainyhead-like 3 (Drosophila) (GRHL3 [MIM 608317]) belongs to a family of three human genes that encode transcription factor orthologs of the Drosophila gene grainy head (grh). Among multiple conserved roles, this gene family is required for the development and repair of the epidermal barrier layer. [1] [2] [3] In zebrafish, grhl1 and grhl3 were shown to be required for the development of the periderm, 4 the transient layer of squamous epithelial cells located on the surface of developing embryos. Interferon regulatory factor 6 (irf6) is also required for periderm development in zebrafish 5 and directly regulates the expression of grhl3. 4, 6 In addition, overexpression of Grhl3 partially rescued periderm development in zebrafish embryos that expressed a dominant-negative mutant form of irf6. 4 These data suggest that Grhl3 is an important player in the Irf6dependent pathway of periderm development.
IRF6 belongs to the IRF family of transcription factors that are known best for their roles in immune function. 7 However, IRF6 (MIM 607199) is required for skin, limb, and craniofacial development. [8] [9] [10] In mice, embryos that lack Irf6 expression fail to develop the epidermal barrier. 9, 10 Although reminiscent of embryos that lack Grhl3, 2 the cutaneous phenotype of Irf6 mutant embryos appears to be more severe macroscopically. In addition, Irf6 mutant embryos have extensive oral epithelial adhesions, 9,10 a phenotype not reported in the Grhl3 mutant. The oral epithelial adhesions in Irf6 knockout embryos lead to cleft palate 9,10 and appear to stem from periderm dysfunction. 4, 11 In humans, mutations in IRF6 cause Van der Woude syndrome (VWS [MIM 119300]), the most common syndromic form of orofacial clefting, or popliteal pterygium syndrome (PPS [MIM 119500]). Individuals with VWS can have cleft lip (CL), cleft palate (CP), or cleft lip and palate (CLP). In addition, 85% of affected individuals have pits in their lower lip. 12 To date, mutations in IRF6 have been identified in 70% of families with VWS. 8, 13, 14 The possibility that locus heterogeneity accounts for some of the remaining 30% of VWS mutations is underscored by linkage in one large pedigree from Finland to a locus on 1p33-p36 rather than to IRF6 at 1q32-q41. 15 In this family, most affected individuals have an orofacial cleft and the proband has lip pits, the hallmark of VWS. Because of the autosomal-dominant inheritance pattern and the presence of the lip pits, this family was diagnosed with VWS and the linked region was named the VWS2 locus. 15 Here we report disease-causing mutations in GRHL3 in the above-mentioned original Finnish family as well as in seven additional families with VWS, thereby demonstrating that GRHL3 is the second gene for which mutations lead to VWS. Although we observed no consistently unique phenotypes in these families, individuals with a GRHL3 mutation are more likely to have CP and less likely to have CL or lip pits than individuals with an IRF6 mutation. In addition, we used zebrafish and murine models to show that Grhl3, like Irf6, has a conserved role in the development of the periderm. Our observations from all three species support the conclusion that a functional oral periderm is essential for the proper palatogenesis.
Material and Methods

Human DNA Samples
DNA samples from 45 families of multiple ethnicities and who were completely sequenced for IRF6 without identifying a causative mutation were used in this study. All subjects were examined by clinical geneticists or genetic counselors who made diagnoses as described previously. [15] [16] [17] Written informed consent was obtained for all subjects and all protocols were approved by the local ethical boards in Helsinki (Finland) or in Stockholm (Sweden) or by the Institutional Review Boards at the University of Iowa (USA). A total of 360 unrelated individuals without a history of oral cleft from the Philippines were used as controls for the GRHL3 (c.1171C>T) Filipino variant and 561 unrelated Finnish individuals (blood donors) were used as controls for the GRHL3 (c.969_970insTG), the PHACTR4 (c.1615G>A; rs200581707), and the KTI12 (c.337_363delCCGATCGCGGGACCTCAGGTGG CGGGC; ss836732090) Finnish variants.
Targeted Exome Sequencing
Genomic DNA from eight affected and three healthy individuals from the VWS2 Finnish family underwent SureSelect Target Enrichment (Agilent Technologies) in order to perform sequence capture of the exome. Enriched samples were sequenced on an Illumina HiSeq instrument. Reads were aligned to reference sequence with the bwa read mapper. 18 A high-quality variant call set was generated based on a best-practice workflow, 19 in which we utilized the Picard and Genome analysis toolkit (GATK) for data processing and analysis.
Genotyping
Genotyping of the GRHL3 c.969_970insTG (Finnish) and c.1171C>T (Filippino) variants and the PHACTR4 (c.1615G>A; rs200581707) Finnish variant was performed with TaqMan SNP Genotyping Assays (Life Technologies) on the ABI Prism 7900HT or ABI 7500 and analyzed with SDS 2.3 or SDS 1.4 software (Applied Biosystems). Family relationships for apparently de novo variants (c.1171C>T and c.1559_1562delGGAG) were confirmed by genotyping 16 markers distributed across the genome (Table S2 available online). The KTI12 (c.337_363delCC GATCGCGGGACCTCAGGTGGCGGGC; ss836732090) variant was genotyped by PCR amplification with SYBR green labeling of the wild-type (100 bp) and the deleted (73 bp) alleles and checked for their respective melting temperatures/curves.
Mutation Screening by Sanger Sequencing
Primers for GRHL3 were designed to amplify the exons of all isoforms of GRHL3 via Primer3. The exons of all four GRHL3 transcript variants were screened in a total of 13 PCR amplicons (Table  S1 ). PCR reactions were incubated at 94 C for 5 min followed by 35 amplification cycles (45 s at 94 C, 45 s at 60 C, 45 s at 72 C) and a final extension at 72 C for 7 min. PCR products were sent for sequencing on an ABI 3730XL (Functional Biosciences). Chromatograms were transferred to a UNIX workstation, base-called with PHRED (v.0.961028), assembled with PHRAP (v.0.960731), scanned by POLYPHRED (v.0.970312), and viewed with the CONSED program (v.4.0). The effects of missense variants were predicted with the Variant Effect Predictor program, 20 which generates scores from PolyPhen2 and SIFT.
Phenotype Analysis
Affected individuals with GRHL3 mutations (n ¼ 27) were assigned a phenotype classification of cleft lip with or without cleft palate (CL/P includes CL and CLP cases), cleft palate (CP), lip pits only, CL/P with lip pits, or CP with lip pits based on the clinical diagnoses. Additional phenotypic classifications described the presence of dental anomalies (hypodontia, dental aplasia, or malocclusion), limb anomalies (syndactyly, polydactyly, club foot, or contractures), or popliteal pterygia. From the set of families positive for IRF6 mutations, 8,13,14,17,21 affected individuals were also assigned to the same phenotype classifications (n ¼ 632). Exclusion criteria for this analysis were individuals with a cleft but without identified familial mutation (i.e., potential phenocopies) and individuals diagnosed with VWS without a known IRF6 or GRHL3 mutation.
Transfection of Human GRHL3 Mutation Variants into Zebrafish Embryos
Full-length, wild-type human GRHL3 cDNA variant 4 (v4) was obtained as a cDNA clone from Open Biosystems (MHS1010-9204655) and shuttled by Gateway cloning into the CS2þ destination vector (kindly provided by Dave Turner, University of Michigan). This construct was used for in vitro synthesis of wild-type GRHL3 mRNA. Specific mutations from VWS-affected individuals were generated in the GRHL3 mRNA (v4) via PCR-mediated mutagenesis and the resulting cDNAs engineered into CS2þ, resulting in the truncation of the first 6 bp of 5 0 UTR and the last 70 bp of 3 0 UTR from mutant variants. These constructs were further used for in vitro synthesis of mutant variants of GRHL3. These truncations (the first 6 bp of 5 0 UTR and the last 70 bp of 3 0 UTR from mutant variants) had no functional consequence, as shown by the fact that we tested a similarly truncated and cloned wildtype GRHL3, and GRHL3 mRNA synthesized from this construct behaved equivalently to full-length GRHL3 in the zebrafish-based functional assay.
Capped mRNA was synthesized in vitro (mMESSAGE mMACHINE SP6 kit, Ambion) and purified with the MEGAclear kit (Ambion) and approximately 1 ng of mRNA was injected into wild-type zebrafish embryos (Scientific Hatcheries outbred strain) at the 1-cell or, for mosaic injections, at the 16-cell stage. Embryos were fixed at 50% epiboly or corresponding time-point (5-6 hpf), and whole-mount in situ hybridization for krt4 was performed as previously described. 22 Plasmids used for probe synthesis are available upon request. Embryos were injected with biotinylateddextran (Invitrogen, D-1956) and processed for visualization as previously described. 4 Animal use protocols were approved by the Public Health Service Assurance.
Murine Crosses
We crossed mice heterozygous for the Irf6 genetrap allele (Irf6 þ/gt ; here referred to as Irf6 þ/À ) 9 with mice heterozygous for the Grhl3 knockout allele (Grhl3 þ/À ) 3 to generate wild-type, Irf6 þ/À , Grhl3 þ/À , and Irf6 þ/À ;Grhl3 þ/À double heterozygous embryos. Grhl3 knockout embryos were obtained by crossing Grhl3 þ/À mice. Presence of a copulation plug was denoted as E0.5. Pregnant dams were injected intraperitoneally with BrdU (Sigma) 2 hr before euthanization at a dose of 100 mg per gram pregnant dam body weight. Embryos were collected at indicated time points and genotyped for Irf6 and Grhl3 null alleles as described previously. 3, 9 Both alleles were maintained on a C57BL/6 background. Animal use protocols were approved by the Institutional Animal Care and Use Committees at Michigan State University and the University of California, Irvine.
Morphological, Histological, and Molecular Analyses of Mice
Gross morphological analysis of the Irf6 þ/À by Grhl3 þ/À cross was done at E13.5, E17.5, P0, and P21. Embryos were then fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at 7 mm intervals. Haematoxylin and eosin staining was performed as described. 9 For immunostaining, antigen retrieval was performed in sodium citrate, followed by blocking steps in BSA and a goat anti-mouse Fab fragment (Jackson ImmunoResearch Laboratories, 115-007-003). Primary antibody was incubated overnight at 4 C and secondary antibody was incubated for 1.5 hr at room temperature. We used primary antibodies against Keratin 6 (Covance, PRB-190 169P), tumor protein p63 (Santa Cruz, 4A4, SC-8431), Irf6 (Sigma-Aldrich, SAB2102995), and Activated Notch1 (Act N1, Cell Signaling, Val1744, D3B8, 4147S). We used the following secondary antibodies: goat anti-rabbit (Molecular Probes, A21429), goat anti-mouse (Molecular Probes, A11029), and goat anti-rat (Molecular Probes, A11006). Nuclei were stained with DAPI (Invitrogen, D3571) followed by slide mounting in ProLong Gold Antifade Reagent (Invitrogen, P36930). 
Imaging
Statistical Analysis
Fisher's exact test in STATA (v.12.1) was used to compare the frequencies of VWS-associated phenotypes between individuals with GRHL3 mutations and those with IRF6 mutations. The threshold p value for this analysis was calculated with a Bonferroni correction (p ¼ 0.05; 8 phenotypes ¼ 0.006). We used chi-square analysis to compare the observed genotype distributions of mice with the predicted Mendelian frequencies. Previous reports show that resorption rates in C57BL/6 mice range between 1% and 3%. We used a two-tailed Fisher's exact test to compare the upper limit of this range with the observed resorption rates.
Results
GRHL3 Is the VWS2 Gene
A single large VWS-affected family of Finnish origin ( Figure S1 ) showed linkage to a~40 cM region on 1p33-36, pointing to a second VWS locus, 15 i.e., VWS2 (MIM 606713). From this family, we selected eight affected individuals, including the proband who is the only one with lip pits, and three healthy individuals for whole-exome sequencing. We searched the~700 genes contained in the entire linkage region (~46 Mb) for variants common to all eight affected family members but not seen in any of the three healthy members. This resulted in three segregating exonic variants in GRHL3 (chr1: 24,666,175; RefSeq accession number NM_198174.2; c.969_970insTG), PHACTR4 (chr1: 28,806,971; rs200581707; RefSeq NM_001048183.1; c.1615G>A), and KTI12 (chr1: 52,499,097-52,499,071; ss836732090; RefSeq NM_138417.2; c.337_363delCCGA TCGCGGGACCTCAGGTGGCGGGC). The GRHL3 and PHACTR4 variants were confirmed by TaqMan genotyping and the KTI12 variant by allelic discrimination based on differential melting temperature. The PHACTR4 variant was found in 2 out of 8,252 European American chromosomes in the NHLBI/ESP database and is therefore unlikely to be the causative variant for VWS. In a set of 561 Finnish controls, the KTI12 variant was found at a frequency of 12.4% and is therefore a common, noncausative variant. The GRHL3 variant was not found in any of the Finnish controls nor in NHLBI/ESP, making GRHL3 a strong candidate gene in the VWS2 locus.
To test whether mutations in GRHL3 accounted for VWS in other families, we screened 44 families of variable ethnicity where no causative IRF6 mutations had been previously detected. We identified GRHL3 variants in seven families, including four protein-truncating mutations and four missense mutations (Figure 1 ). All mutations except c.1661A>G (coding for the p.Asn554Ser missense alteration) were predicted by PolyPhen2 and SIFT to be damaging/deleterious and two were confirmed de novo events ( Table 1 ). In one of the seven families (VWS-III), we found two variants located in trans. Variant c.268_278delTACTACCATGG was inherited from the proband's affected father and from the healthy paternal grandfather, and variant c.1661A>G was inherited from the proband's healthy mother ( Figure S1 ). In addition, one family (VWS-IV) was previously determined to have a novel IRF6 missense variant (c.239A>G) that was not conclusively determined to be causative for VWS, 23 raising the possibility that variants in both IRF6 and GRHL3 could contribute to VWS in one family ( Figure S1 ).
We tested for phenotypic variation between the VWS and VWS2 loci. The phenotypes observed in the individuals with mutations in GRHL3 overlap with the classic VWS phenotype ( Figure S1 ). However, individuals positive for a GRHL3 mutation were significantly more likely to have CP (70% [GRHL3] versus 27% [IRF6], p value ¼ 2.0 3 10 À6 ) and less likely to have CL/P (CL or CLP) (11% versus 46%, p value ¼ 0.001) than individuals with IRF6 mutations ( Table 2 ). Lip pits were less frequent among individuals with GRHL3 mutations (52% versus 76%), but this difference was not statistically significant (p value ¼ 0.05). The presence of dental and limb anomalies did not differ significantly between the two groups.
Effect of GRHL3 Alleles on Zebrafish Development
To distinguish whether the human GRHL3 alleles that cause VWS are nulls or dominant negative, we developed an in vivo assay to measure the function of the gene on the development of the periderm in zebrafish. 4 The assay is based on the observation that overexpression of wild-type grhl3 in zebrafish or frog embryos (Xenopus laevis) is sufficient to induce, in deep cells, ectopic expression of genes whose expression is normally restricted to the periderm, e.g., keratin 4 (krt4). 4,24 Also, simultaneous reduction of grhl1 and grhl3, or overexpression of an engineered dominant-negative variant of frog grhl1, prevents the expression of krt4 in epithelial cells of the zebrafish periderm and causes embryonic death during epiboly. 4 Therefore, we injected wild-type and mutant alleles of human GRHL3 mRNA into zebrafish embryos and scored for embryonic viability and krt4 expression. At shield stage (6 hr postfertilization, hpf), most embryos injected with a control mRNA (lacZ) developed normally, and krt4 expression was confined to the periderm (Figures 2A and 2E) . In most embryos injected with wild-type GRHL3, epiboly was slightly delayed in comparison to lacZ-injected control embryos ( Figure 2B ) and krt4 was ectopically expressed in deep cells ( Figure 2F) . In contrast, the majority of embryos injected with GRHL3 mRNA carrying the c.1171C>T variant from VWS-II stalled before (4 hpf) or during epiboly stage, and then ruptured through the animal hemisphere ( Figure 2C ). This phenotype resembles that of embryos injected with the dominant-negative alleles of Xenopus grhl1 or zebrafish irf6. 4 
,5 We tested four other VWS-associated alleles of GRHL3 with this in vivo assay, including both alleles found in VWS-III. For all four alleles, embryonic development stalled and the embryo ruptured at a time point and frequency similar to embryos injected with the c.1171C>T variant from VWS-II (Figure 2D).
To test whether the effect of these mutations was cell autonomous, we generated mosaic embryos by coinjecting GRHL3 mRNA and biotin into one cell at the 16-cell stage of zebrafish development. In this assay, cells that inherited the GRHL3 mRNA were marked by biotin staining. In embryos injected with control mRNA (LacZ), we observed normal krt4 expression in all periderm cells, regardless of the biotin staining ( Figure 2G ). In embryos injected with GRHL3 mRNA containing the c.893G>A variant (from VWS-IV), the cells from the periderm inheriting the mutated mRNA (biotin-positive) lacked krt4 expression, but biotin-negative cells expressed krt4 ( Figure 2H ). We conclude that mutant GRHL3 variant interfered with the development of the periderm in a cell-autonomous fashion. In summary, each of the five GRHL3 mutations appeared to encode a protein with dominant-inhibitory effect that disrupted the development of the periderm through a cell-autonomous mechanism.
Grhl3 À/À Murine Embryos Have Cleft Palate at Low Penetrance
To identify a potential common mechanism for orofacial clefts in individuals with VWS, we compared the oral phenotype of murine embryos that lack Irf6 (Irf6 À/À ) to embryos that lack Grhl3 (Grhl3 À/À ). Wild-type embryos at E15.5 had normal oral epithelium and a fully fused palate ( Figure 3A) , whereas Irf6 À/À embryos (n ¼ 4) had extensive epithelial adhesions between the palatal shelves and the lingual, mandibular, and maxillary surfaces ( Figure 3B ). 9,10 These adhesions prevented the palatal shelves from elevating and led to a cleft palate in all embryos. Similarly, all Grhl3 À/À embryos at E15.5 had bilateral oral epithelial adhesions (n ¼ 6) and one of these embryos had a cleft palate ( Figure 3C) . Thus, Grhl3, like Irf6, is required for palatal development.
To compare the histological changes in these two mutant strains, we immunostained with keratin 6 (Krt6), a marker for the periderm, 25 and tumor protein p63 (p63), a marker for the basal epithelial layer. 26 We detected Krt6 in the oral periderm of wild-type embryos ( Figure 3D ), but Krt6 expression was strongly reduced in the epithelium superficial to the tooth germs in both Irf6 À/À and Grhl3 À/À mutant embryos (Figures 3E and 3F) . Similar results were observed for activated Notch1 (Act N1) ( Figure S3 ), another protein expressed in the periderm. 11 Thus, we concluded that both Irf6 and Grhl3 were required for proper development of the oral periderm in the mouse. In addition to its potential role in the periderm, Irf6 regulates the differentiation of the keratinocytes in the epidermis 9,10 and the oral cavity. 11 In the oral cavity, wildtype embryos had a uniform, single layer of basal epithelium ( Figure 3D) , whereas the basal layer in Irf6 À/À embryos was disorganized and thicker, and p63 was ectopically expressed in the cells of the suprabasal layer ( Figure 3E) . In Grhl3 À/À embryos, the basal epithelial layer appeared grossly normal with normal expression of p63 ( Figure 3F ). We also looked at the medial edge epithelium (MEE), the epithelium located at the medial edge of the palatal shelves that must dissolve for proper palatal fusion. In wild-type ( Figure 3G) and Grhl3 À/À (Figure 3I) Figure 3H ). 11 Thus, Irf6 À/À embryos have at least two problems during palatal development: the presence of oral epithelial adhesions and the failure of the MEE to dissolve. In contrast, Grhl3 À/À embryos have only oral epithelial adhesions because of the loss of periderm. Because mutations in both these genes cause VWS, these results are consistent with the hypothesis that abnormal periderm function contributes to CL/P in humans.
embryos, the MEE dissolved to form a confluent bridge of mesenchymal cells across the palate as shown by the loss of expression of p63. In contrast, although we do not know the exact location of the MEE in Irf6 À/À embryos, expression of p63 persisted throughout the epithelium of the palatal shelves (
The Oral Phenotypes of Irf6 and Grhl3 Heterozygous Murine Mutants Are Independent Based on ChIP-seq experiments on a human keratinocyte cell line and epistasis experiments in zebrafish embryos,
we hypothesized that Irf6 and Grhl3 function in a common pathway. 4, 6 To test for epistasis during murine palatogenesis, we generated embryos that were heterozygous for both Irf6 and Grhl3 (Irf6 þ/À ;Grhl3 þ/À ). As expected, we did not observe any oral epithelial adhesions in wild-type embryos (Figures 4A and 4D) . In Irf6 þ/À embryos we detected bilateral oral adhesions at the tooth germ sites ( Figure 4B ). We also observed bilateral epithelial abnormalities in Grhl3 þ/À embryos ( Figure 4E ), but they differed from those seen in the Irf6 þ/À embryos in three respects. First, whereas oral adhesions in Irf6 þ/À embryos were more prominent at the tooth germ sites (Figure 4B) , epithelial abnormalities in Grhl3 þ/À embryos were located throughout the oral cavity and most frequently posterior to the tooth germs ( Figure 4E) . Second, epithelial abnormalities included oral fusions ( Figure 4E) , which do not occur in Irf6 þ/À embryos. Here, we distinguish oral epithelial adhesions from oral fusions histologically.
Whereas adhesions have a loss of periderm that allows cell interactions between two adjacent epithelial layers, fusions have a loss of both the periderm and the basal epithelial layers that allows cell interactions between the underlying mesenchymal cells from adjacent tissues. Finally, whereas oral adhesions in
Irf6 þ/À occurred most frequently between the mandible and maxilla, oral fusions in Grhl3 þ/À embryos occurred between the mandible and either the palate or the maxilla. In the Irf6 þ/À ;Grhl3 þ/À double heterozygous embryos, we found oral adhesions at areas superficial to the tooth germ ( Figure 4C ), similar to Irf6 þ/À embryos, as well as oral adhesions and fusions posterior to the tooth germ ( Figure 4F ), similar to Grhl3 þ/À embryos. Thus, the oral histopathology of the Irf6 þ/À ;Grhl3 þ/À double heterozygote embryos provides no evidence for epistasis and suggests that Irf6 and Grhl3 function in independent but converging pathways during oral periderm development.
As previously observed in the single knockout Irf6 À/À and Grhl3 À/À embryos, we detected a reduction in Figure 4G versus 4H and 4I) and a more apparent reduction of Krt6 in the double heterozygous embryos (Figure 4J) . At higher magnification, the loss in Krt6 staining coincided with the loss of oral periderm cells ( Figure 4K  versus 4L-4N ). We did not detect any change in p63 expression in the Irf6 þ/À embryos (Figure 4O versus 4P) . However, in the Grhl3 þ/À (Figure 4Q ) and the Irf6 þ/À ; Grhl3 þ/À ( Figure 4R ) embryos, we observed a loss of expression of p63, indicating a loss of the basal epithelial cells at the sites of the oral fusions. Again, these molecular data suggest that Irf6 and Grhl3 function independently during palatal development.
Although we did not detect epistasis between Irf6 and Grhl3 during palatal development, we observed a 12% (6/51) rate of resorbing embryos (Table S3 ). This frequency was significantly higher than expected (3%, p value ¼ 0.0008) for the C57BL/6 murine strain. 27 In addition, although we observed a Mendelian distribution of pups at birth (postnatal day 0, P0), Irf6 þ/À ;Grhl3 þ/À pups were significantly underrepresented at P21 (p value ¼ 0.01). Thus, prenatal and postnatal lethality from crosses that generated the double heterozygous pups suggest positive epistasis between Irf6 and Grhl3 at other time points and/or tissues during development.
Discussion
By using a combination of whole-exome and Sanger sequencing methods, we identified mutations in GRHL3 in eight families with VWS that had no causative mutations in IRF6, thus demonstrating that, when mutated, GRHL3 is the gene responsible for VWS at the VWS2 locus. Although previous studies had found IRF6 mutations in 70% of families with VWS, there had been very little evidence for locus heterogeneity. Despite 15 published linkage studies on 49 families from throughout the world, 28 only one pedigree demonstrated linkage outside of the IRF6 locus. 15 Because this family originated from Finland, a relatively isolated population, and because, at that time, only one member of the family had lip pits, the cardinal feature of VWS, the broader impact of this family on VWS genetics was uncertain. However, the finding of causative mutations in seven additional families from broad geographic and phenotypic spectra supports the clinical and biological significance of this locus for VWS and demonstrates that locus heterogeneity contributes to the genetic architecture of VWS.
The results from our mutation screen also suggest a complex allelic architecture for GRHL3 in VWS. Based on the precedent of IRF6, we hypothesized that VWS resulting from mutation at the second locus (VWS2) would be caused by haploinsufficiency of GRHL3. Consistent with this hypothesis, we observed both missense and protein truncation mutations. In addition, the DECIPHER database (Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources) 29 includes a 1.9 Mb de novo deletion encompassing GRHL3 in an individual with CP, club foot, developmental delay, prominent forehead, and a thin upper lip. In our small number of cases, we also observed a case of compound In contrast, Irf6 À/À embryos have bilateral oral adhesions (arrows) and a fully penetrant cleft palate (asterisk) (B). Similarly, Grhl3 À/À embryos have bilateral oral adhesions (arrows) (C). However, in Grhl3 À/À embryos, adhesions were restricted to areas superficial to the tooth germ and palatal surfaces, and a cleft palate was observed in one of six embryos (asterisk) (C). (D-F) Immunostaining for Krt6 (red) and p63 (green). Krt6 was expressed uniformly in the periderm superficial to the tooth germ (arrow) of wild-type embryos (D) (from boxed structure in A) but was very weakly expressed in Irf6 À/À (E) and Grhl3 À/À (F) embryos. p63 was expressed uniformly in the basal epithelium of wildtype (D) and Grhl3 À/À (F) embryos but was expressed ectopically in suprabasal cells in Irf6 À/À embryos (E). heterozygous alleles for GRHL3 (proband in VWS-III) and another case with a rare variant in both IRF6 and GRHL3 (proband in VWS-IV). However, all five GRHL3 variants used in the zebrafish assay, including both alleles of the compound heterozygote individual, uniformally tested as dominant negative. If VWS-associated GRHL3 alleles also have a dominant-negative effect in human tissues, it is not clear why they would be found in a coupled state, how the protein truncation alleles remain stable, and whether GRHL3 participates in protein complexes. Further genetic and biochemical studies will be required to understand the effects of these alleles in human tissues.
(G-I) Loss of p63 expression marks normal dissolution of the medial edge epithelium (MEE) (arrowhead) in wild-type (G) and Grhl3
The analysis of human phenotypes suggests two clinical hypotheses. First, because individuals with GRHL3 mutations were more likely to have CP and less likely to have CL/P than individuals with IRF6 mutations, this association may be used to prioritize these two genes for mutation screens in VWS cases. We note that this association was made from a small number of individuals with GRHL3 mutations (n ¼ 27) and that nine individuals originated from one family (VWS-I). However, when we restricted the analysis to a family-based phenotype (n ¼ 8), we observed the same trends, although not achieving statistical significance because of low power. Second, like IRF6, common DNA variants in GRHL3 may also be associated with isolated forms of orofacial clefting, 30 especially for CP, given the increased likelihood of CP in individuals with a mutation in GRHL3. However, multiple genome-wide association studies for CL/P 31 and one for CP 32 have not provided strong evidence for common variants at the GRHL3 locus. Although these studies suggest that common DNA variants in GRHL3 do not account for significant risk for CL/P or CP, GRHL3 remains an excellent candidate gene for isolated orofacial clefts.
Finally, our analysis of phenotypes in Irf6 and Grhl3 mutant mice identified common and distinct oral abnormalities. Previous studies revealed that Irf6 deficiency in mice could lead to an orofacial cleft by at least two pathophysiological mechanisms: abnormal periderm differentiation and failure of the medial edge epithelium (MEE) to dissolve. 11, 33 The MEE was able to dissolve normally in embryos that lack Grhl3, so the common feature of Irf6 and Grhl3 mutants is failed periderm differentiation, strengthening the previously hypothesized role of periderm in development of the lip and palate.
In conclusion, these studies identify GRHL3 as the second gene that when mutated leads to Van der Woude syndrome, thus confirming locus heterogeneity for this syndrome. Further, they strengthen the connection between cleft palate and abnormal periderm development. We anticipate that these findings will improve the molecular diagnostic for VWS and other forms of orofacial clefting.
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